Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | GCGR | P47871 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.53 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5897234 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL1719679 | 0.86 | ALDH1A1 (0.57) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL3278029 | 0.82 | GCGR (0.61) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL20254477 | 0.78 | PTPN5 (0.53) | ALDH1A1MAPTSMN1; SMN2GAAKDM4E | |
| SCHEMBL2649274 | 0.77 | GCGR (0.76) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL1719562 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MAPTSMN1; SMN2LMNANPSR1 | |
| SCHEMBL5897153 | 0.76 | ALDH1A1 (0.40) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL2647883 | 0.75 | GCGR (0.73) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL2647850 | 0.74 | GCGR (1.00) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR | |
| SCHEMBL2649360 | 0.74 | GCGR (0.72) | ALDH1A1MAPTSMN1; SMN2LMNAGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1576110-A4 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2007011647-A2 | INHIBITORS OF MITOTIC KINESIN KSP | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-7012100-B1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060035958-A1 | Method of treating diabetes and related conditions | MERCK & CO., INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1576110-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | Avolix Pharmaceuticals (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1538903-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024066-A2 | METHOD OF TREATING DIABETES AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128742-A1 | Cell migration inhibiting compositions and methods and compositions for treating cancer | MKI67, DCX, NUDC | ALDH1A1 1944/4885MAPT 3866/4885SMN1; SMN2 4264/4885 |
| US-20060035958-A1 | Method of treating diabetes and related conditions | GLP1R, GPR119, GCGR | ALDH1A1 2972/4885MAPT 4230/4885SMN1; SMN2 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.